The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes

Author(s):
Bus, P.; Scharpfenecker, M.; Wilk, P. van der; Wolterbeek, R.; Bruijn, J.A. (0000-0001-7592-250X); Baelde, H.J.
Published
2017
Publication type
Article / Letter to editor
AlbuminuriaDiabetic nephropathyEndothelial activationGlomerular damageInflammationRenal functionsFLT-1VEGF-A
Date issued
2017-09-30
Language
English
Is part of
Diabetologia (2017), Vol. 60, no. 9, p. 1813-1821
hdl
1887/94746
doi
10.1007/s00125-017-4322-3